Candel Therapeutics stock up 172% after Phase III prostate cancer success

Candel Therapeutics stock up 172% after Phase III prostate cancer success

Submitted by admin on December 11, 2024 - 11:19am
Source: 
Clinical Trials Arena
News Tags: 
Candel Therapeutics
clinical trials
prostate cancer
CAN-2409
Headline: 
Candel Therapeutics stock up 172% after Phase III prostate cancer success
snippet: 

The company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study.

Do Not Allow Advertisers to Use My Personal information